Inhibikase Therapeutics, Inc. (IKT) vs Vanda Pharmaceuticals Inc. (VNDA)
A side-by-side comparison of Inhibikase Therapeutics, Inc. and Vanda Pharmaceuticals Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IKT
Inhibikase Therapeutics, Inc.
$1.98HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
VNDA
Vanda Pharmaceuticals Inc.
$4.52HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — IKT vs VNDA
growth of $100 · dividends reinvested · last 6yIKT -96.6% (-43.2%/yr)VNDA -64.9% (-16.0%/yr)VNDA compounded faster over this window
Log scale — wide-divergence pair
IKT VNDA
IKT vs VNDA: by the numbers
- •VNDA is the larger company ($272M vs $261M market cap).
- •Both run net losses; IKT's is the smaller (0.00% vs -127.41% net margin).
Metrics side by side
Valuation
| Metric | IKT | VNDA |
|---|---|---|
| P/S ratio | N/A | 1.26 |
| P/B ratio | 1.71 | 1.23 |
Profitability
| Metric | IKT | VNDA |
|---|---|---|
| Gross margin | 0.00% | 92.82% |
| Operating margin | 0.00% | -69.95% |
| Net margin | 0.00% | -127.41% |
| ROE | -39.55% | -124.83% |
| ROIC | -42.92% | -74.73% |
Growth (annualized)
| Metric | IKT | VNDA |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -3.56% |
| Total return CAGR (5Y) | -29.10% | -23.91% |
Frequently asked
- How have IKT and VNDA total returns compared?
- Over the past 5 years, IKT delivered -29.10% and VNDA delivered -23.91% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.